RE-CONNECT: Understanding Connection, Intimacy & Peptide/Hormone Research
RE-CONNECT is an educational resource about human connection, intimacy, sexual health, oxytocin biology, and current research involving oxytocin and BPC-157.
Human intimacy is complex. Emotional connection, sexual health, desire, arousal, relationship satisfaction, and physical intimacy can be influenced by psychological, neurological, hormonal, medical, social, and relationship factors.
Research has investigated the biological systems involved in bonding, social interaction, stress, sexual behavior, and interpersonal connection.
However, identifying a biological pathway associated with intimacy does not establish that altering that pathway with a hormone, peptide, or medication will improve a relationship or sexual function.
Understanding Connection & Intimacy
Connection and intimacy involve considerably more than a single hormone or biological process.
Factors that can influence intimacy include:
Persistent concerns deserve individual evaluation:
Changes in desire, arousal, sexual function, or emotional connection can sometimes also be associated with underlying medical or psychological conditions. Persistent concerns should therefore be evaluated individually rather than assumed to result from a single hormonal imbalance.
Understanding Oxytocin
Oxytocin is a naturally occurring peptide hormone produced primarily in the hypothalamus and released through the posterior pituitary. It has well-established physiological roles in childbirth and lactation.
Oxytocin is also involved in complex neurological pathways associated with:
These associations have led researchers to investigate whether oxytocin may influence aspects of social connection and intimate behavior. However, human social behavior is extraordinarily complex, and oxytocin should not simply be characterized as a “love hormone” or “bonding hormone.”
A systematic review and meta-analysis involving 63 studies found substantial methodological differences across studies examining endogenous oxytocin and human social interaction, with results that did not consistently support a simple relationship between social interaction and oxytocin response. PubMed Central (PMC)
Oxytocin & Sexual Health Research
Researchers have also studied oxytocin in relation to sexual arousal, orgasm, sexual behavior, and partner interaction. A systematic review examining oxytocin and human sexual behavior identified 13 eligible studies and reported that many found increased oxytocin concentrations around orgasm or ejaculation. The authors emphasized the complexity of interpreting oxytocin's role in human sexual behavior. PubMed
A randomized study involving 29 healthy heterosexual couples investigated intranasal oxytocin during sexual activity. The study did not find improvements in classical measures such as sexual drive, arousal, erection, or lubrication. Researchers did report some differences involving orgasmic/post-orgasmic experiences and aspects of partner interaction, with generally small-to-moderate effects. PubMed
A broader review similarly concluded that human studies have not consistently reproduced the facilitatory effects on sexual behavior observed in animal research. PubMed
Formulation & Route Distinction:
This is particularly important for RE-CONNECT because research involving intranasal oxytocin should not automatically be applied to an oral oxytocin formulation. Formulation and route of administration can affect absorption, exposure, biological activity, and available safety evidence.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide that has been investigated primarily in laboratory and animal research.
The human evidence remains extremely limited. A 2026 review reported fewer than 30 subjects across three published uncontrolled human pilot studies and concluded that the available evidence does not support evidence-based clinical recommendations for any indication. PubMed
Importantly for RE-CONNECT, BPC-157 has not been established as a treatment for intimacy, relationship connection, sexual dysfunction, or sexual desire. Its inclusion alongside oxytocin should not imply that the two substances have been clinically demonstrated to work together for these purposes.
Understanding the Evidence
Oxytocin and BPC-157 have very different research histories.
Oxytocin is an endogenous human hormone with established physiological functions and extensive scientific research. Research involving oxytocin has examined social interaction, bonding, stress responses, sexual physiology, childbirth, and lactation. However, research into oxytocin's role in human connection and sexual behavior has produced complex and sometimes inconsistent findings. PubMed
BPC-157 has a substantially smaller human evidence base, with most published research remaining preclinical. PubMed
There is not sufficient clinical evidence to present the combination of BPC-157 + oxytocin as an established treatment for improving relationships, increasing emotional attachment, increasing sexual desire, improving sexual performance, treating sexual dysfunction, or restoring intimacy.
Understanding Sexual & Relationship Health
Changes in intimacy or sexual function can have many possible contributors.
Depending upon the individual, these may include:
Regulatory & Safety Considerations
Oxytocin and BPC-157 have substantially different regulatory statuses and should not be presented as though they are equivalent.
Oxytocin exists in FDA-approved prescription products for specific medical indications. This does not mean that every formulation, route of administration, or proposed use of oxytocin is FDA-approved. Research involving intranasal oxytocin, for example, does not establish the safety or effectiveness of an oral compounded oxytocin product for connection or intimacy.
BPC-157 is not a component of an FDA-approved drug. FDA currently states that compounded drugs containing BPC-157 may present immunogenicity risks for certain routes of administration and may involve complexities associated with peptide-related impurities and active pharmaceutical ingredient characterization. FDA says available safety information is limited. U.S. Food and Drug Administration
FDA's Pharmacy Compounding Advisory Committee also considered BPC-157-related bulk substances in July 2026; the use FDA evaluated for BPC-157 in that proceeding was ulcerative colitis, not intimacy or sexual function. U.S. Food and Drug Administration
Compounded drugs are not FDA-approved and should not be represented as though FDA has evaluated them for safety and effectiveness for their proposed compounded use.
Questions to Discuss With a Healthcare Professional
Patients learning about connection, intimacy, sexual health, and hormone or peptide research may wish to ask:
Continuing Research
Research into oxytocin continues to explore its complex roles in social behavior, stress responses, interpersonal interaction, sexual physiology, and brain activity.
Additional controlled human research would be needed to determine whether investigational applications translate into safe and clinically meaningful outcomes. Patients should distinguish among normal human physiology, experimental research, established medical treatments, compounded preparations, and FDA-approved uses when evaluating information about hormones and peptides.
Educational Resources & Citations
This page is provided for general educational purposes only. It is not intended to provide medical advice, diagnosis, relationship counseling, or treatment.
References to oxytocin, BPC-157, intimacy, sexual health, neurological pathways, biological mechanisms, laboratory research, animal studies, or areas of clinical investigation are provided for educational purposes and should not be interpreted as a recommendation or endorsement of a particular substance or treatment.
Discussion of oxytocin's biological role in social or sexual behavior does not establish that a particular oxytocin product or route of administration improves relationships, emotional connection, sexual desire, sexual performance, or sexual function.
Discussion of BPC-157 does not establish that it is safe, effective, FDA-approved, or appropriate for connection, intimacy, or sexual-health concerns.
Individuals experiencing persistent changes in sexual function, desire, emotional well-being, or intimate relationships should consider evaluation by an appropriately qualified healthcare, mental-health, relationship, or sexual-health professional.
Treatment decisions should be individualized based on medical history, current health, medications, symptoms, potential risks, available clinical evidence, and professional clinical judgment.
FDA approval status, compounding policies, clinical evidence, and regulatory requirements may change. Current information should be verified through the U.S. Food & Drug Administration and recognized medical resources.